Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.

Mutations in DNA damage repair genes, in particular genes involved in homology-directed repair, define a subgroup of men with prostate cancer with a more unfavorable prognosis but a therapeutic vulnerability to PARP inhibition.